613 related articles for article (PubMed ID: 24061039)
1. Gastric cancer-molecular and clinical dimensions.
Wadhwa R; Song S; Lee JS; Yao Y; Wei Q; Ajani JA
Nat Rev Clin Oncol; 2013 Nov; 10(11):643-55. PubMed ID: 24061039
[TBL] [Abstract][Full Text] [Related]
2. Personalised Treatment in Gastric Cancer: Myth or Reality?
Tarazona N; Gambardella V; Huerta M; Roselló S; Cervantes A
Curr Oncol Rep; 2016 Jul; 18(7):41. PubMed ID: 27215435
[TBL] [Abstract][Full Text] [Related]
3. Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review.
Zagouri F; Papadimitriou CA; Dimopoulos MA; Pectasides D
Cancer Treat Rev; 2011 Dec; 37(8):599-610. PubMed ID: 21676549
[TBL] [Abstract][Full Text] [Related]
4. Targeting the MET Pathway in Gastric and Oesophageal Cancers: Refining the Optimal Approach.
Lee J; Tran P; Klempner SJ
Clin Oncol (R Coll Radiol); 2016 Aug; 28(8):e35-44. PubMed ID: 26880063
[TBL] [Abstract][Full Text] [Related]
5. Current advances in targeted therapies for metastatic gastric cancer: improving patient care.
Aguiar PN; Muniz TP; Miranda RR; Tadokoro H; Forones NM; Monteiro ID; Castelo-Branco P; Janjigian YY; De Mello RA
Future Oncol; 2016 Mar; 12(6):839-54. PubMed ID: 26838766
[TBL] [Abstract][Full Text] [Related]
6. Recent updates of precision therapy for gastric cancer: Towards optimal tailored management.
Joo MK; Park JJ; Chun HJ
World J Gastroenterol; 2016 May; 22(19):4638-50. PubMed ID: 27217696
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
8. Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.
Ali SM; Sanford EM; Klempner SJ; Rubinson DA; Wang K; Palma NA; Chmielecki J; Yelensky R; Palmer GA; Morosini D; Lipson D; Catenacci DV; Braiteh F; Erlich R; Stephens PJ; Ross JS; Ou SH; Miller VA
Oncologist; 2015 May; 20(5):499-507. PubMed ID: 25882375
[TBL] [Abstract][Full Text] [Related]
9. Targeted therapy in advanced gastric carcinoma: the future is beginning.
Schinzari G; Cassano A; Orlandi A; Basso M; Barone C
Curr Med Chem; 2014; 21(8):1026-38. PubMed ID: 24304282
[TBL] [Abstract][Full Text] [Related]
10. Changing strategies for target therapy in gastric cancer.
Lee SY; Oh SC
World J Gastroenterol; 2016 Jan; 22(3):1179-89. PubMed ID: 26811656
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapies for advanced and metastatic adenocarcinoma of the gastroesophageal junction: is there something new?
Pasini F; Fraccon AP; Modena Y; Bencivenga M; Giacopuzzi S; La Russa F; Gusella M; de Manzoni G
Gastric Cancer; 2017 Jan; 20(1):31-42. PubMed ID: 27568322
[TBL] [Abstract][Full Text] [Related]
12. The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.
Aprile G; Giampieri R; Bonotto M; Bittoni A; Ongaro E; Cardellino GG; Graziano F; Giuliani F; Fasola G; Cascinu S; Scartozzi M
Expert Opin Investig Drugs; 2014 Jul; 23(7):925-42. PubMed ID: 24806575
[TBL] [Abstract][Full Text] [Related]
13. Targeted therapies for gastric cancer: current status.
Yoong J; Michael M; Leong T
Drugs; 2011 Jul; 71(11):1367-84. PubMed ID: 21812503
[TBL] [Abstract][Full Text] [Related]
14. Molecular targeted treatment and drug delivery system for gastric cancer.
Jiang L; Gong X; Liao W; Lv N; Yan R
J Cancer Res Clin Oncol; 2021 Apr; 147(4):973-986. PubMed ID: 33550445
[TBL] [Abstract][Full Text] [Related]
15. Current and emerging therapies in unresectable and recurrent gastric cancer.
Jou E; Rajdev L
World J Gastroenterol; 2016 May; 22(20):4812-23. PubMed ID: 27239108
[TBL] [Abstract][Full Text] [Related]
16. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Cheremisina OV; Volkov MY; Choynzonov EL; Gorbunov AK; Usynin EA
Curr Drug Targets; 2020; 21(7):713-721. PubMed ID: 31775598
[TBL] [Abstract][Full Text] [Related]
17. Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.
Díaz-Serrano A; Angulo B; Dominguez C; Pazo-Cid R; Salud A; Jiménez-Fonseca P; Leon A; Galan MC; Alsina M; Rivera F; Plaza JC; Paz-Ares L; Lopez-Rios F; Gómez-Martín C
Oncologist; 2018 Sep; 23(9):1092-1102. PubMed ID: 29700210
[TBL] [Abstract][Full Text] [Related]
18. Update on metastatic gastric and esophageal cancers.
Shah MA
J Clin Oncol; 2015 Jun; 33(16):1760-9. PubMed ID: 25918288
[TBL] [Abstract][Full Text] [Related]
19. Novel targeted agents for gastric cancer.
Liu L; Wu N; Li J
J Hematol Oncol; 2012 Jun; 5():31. PubMed ID: 22709792
[TBL] [Abstract][Full Text] [Related]
20. mTOR as a therapeutic target in patients with gastric cancer.
Al-Batran SE; Ducreux M; Ohtsu A
Int J Cancer; 2012 Feb; 130(3):491-6. PubMed ID: 21898386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
